Citations

Clear

200 citation(s) found for "Sherry, DD".

Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
Greenberg, Steven M. , Iadecola, Costantino , Chou, Sherry , Cogswell, Petrice M, Elkind, Mitchell S.V. , II, William J. Hicks, Le, Caitlin, Levine, Deborah A. , Lipton, Richard B. , Massimo, Lauren, Mohl, Stephanie M. , Snyder, Heather M. , Yaffe, Kristine , Adams, Robert, Agronin, Marc, Atri, Alireza, Bauman, Mary Ann, Bernat, James L., Biffi, Alessandro , Blum, Sonja, Bussiere, Thierry, Carrillo, Maria C., Chiang, Gloria, Cato, Kenrick, Chaitoff, Alexander, Bakken, Suzanne, Schelke, Matthew W. , Cruz‐Flores, Salvador, Derdeyn, Colin, Dhand, Amar, Evans, David A., Gettel, Cameron, Goldstein, Larry B, Grill, Joshua, Kulshrestha, Ambar, Lam, Christine, Lazar, Ronald M. , Li, Hanlin , Madsen, Tracy, Ramanan, Vijay K., McCullough, Louise, Merino, José G., Orjuela, Karen, Guo, Michael, Messe, Steve, Tubiello, Maggie, Ruff, Christian T., Selim, Magdy, Sha, Sharon J., Sheth, Kevin, Stamm, Brian, Buckwalter, Marion, Skylar-Scott, Irina, Lavretsky, Helen, Saver, Jeffrey, Rabinovici, Gil D., VandeVrede, Lawren, Goyal, Manu S., Weisman, David C., Lipton, R.B. , Chou, Sherry H-Y , Seshadri, Sudha , Snyder, Heather M , Yaffe, Kristine , Zachrison, Kori S , Cogswell, Petrice M. , Hicks, William J., Massimo, Lauren , Seshadri, Sudha , Atri, Alireza, Blum, Sonja, Bussière, Thierry , Carlisle, Tara C. , Chaitoff, Alexander , Cruz-Flores, Salvador, Chyou, Janice Y. , Derdeyn, Colin P. , Gettel, Cameron J. , Goldstein, Larry B. , Grill, Joshua D. , Ishii, Makoto , Kulshreshtha, Ambar , Rabinstein, Alejandro A. , Ramanan, Vijay K. , McCullough, Louise D. , Merino, José G. , Messé, Steven R. , Ruff, Christian Thomas , Saklad, Stephen R. , Selim, Magdy H. , Shah, Sachin J. , Stamm, Brian , Buckwalter, Marion S. , Skylar-Scott, Irina A., Rabinovici, Gil D. , VandeVrede, Lawren , Chatterjee, Arindam R , Wunderink, Richard G.

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048108 | PMID 42622140 Get It

Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. Methods The American Heart Association convened 75 multidisciplinary experts for the Amyloid‐Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus‐based guidance for clinicians. Results This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co‐occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision‐making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. Conclusions Building on lessons learned from the establishment of stroke systems of care, the consensus‐based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground‐breaking therapies.
Device and Data Access Considerations for Digital Health Studies Using Consumer‐Grade Wearables: An Experience‐Based Tutorial
Zhu, Mike , Spencer, Joshua D., Chesak, Sherry, Romanowicz, Magdalena , Chauhan, Mohit , Athreya, Arjun P. , Athreya, Arjun P , Chauhan, Mohit , Chesak, Sherry S. , Dyrbye, Liselotte N. , Croarkin, Paul E. , Bobo, William V.

Mayo Clinic

Clinical and Translational Science | August 5, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1111/cts.70693 | PMID 42552672 Get It

ABSTRACT Consumer‐grade wearables, including smartwatches, fitness trackers, and smart rings, are accessible tools for studying pharmacologic responses in real‐time, monitoring participant health in decentralized clinical trials, optimizing outcome measures, and delivering digital interventions that promote behavior change. However, incorporating consumer wearables into clinical studies is not as straightforward as simply purchasing devices and providing them to participants. It requires engaging with a complex engineering ecosystem with multiple investigator decisions on device selection, associated data management practices, and patient/participant engagement and technical support. This tutorial, based on experience running large clinical trials using consumer wearables, outlines the wearables market landscape across varying form factors and manufacturers as well as the data management software products supporting wearable use. It delineates the major decision processes involved in designing studies that incorporate wearables and presents a structured framework to guide the selection of devices and supporting data tools according to study objectives.
Clinical Recommendations for Remote Robotic Assisted Surgery From the CRSA 2025 International Consensus Conference
Raptis, Dimitri Aristotle , Kavoussi, Louis, Wren, Sherry M. , Fowler, Dennis, Anvari, Mehran, Bianco, Francesco, Liang, Xiao, Li, Zheyong, Yin, Xiaoyu, Piccoli, Micaela, Marks, John, Shen, Baiyong, Ko, Clifford, Seeliger, Barbara, Hagendoorn, Jeroen, Essani, Rahila, Walsh, R. Matthew, Oleynikov, Dmitry, Jones, Stephanie B., Bindal, Vivek , Kim, Hyun Koo, Hyung, Woo Jin, Hashimoto, Daniel, Chen, Liaohai Leo, Burt, Bryan M., Lafaro, Kelly, Elli, Fernando, Wilson, Erik, Bianchi, Paolo Pietro, Morgan, Annette, Bartlett, Stephen T., Rashidi, Laila, Yu, Liu, Gawkins, Bill, Hinoul, Piet, Peine, Bill, Woo, Yanghee, Raoof, Mustafa, Jones, Daniel, Deshpande, Supriya, Bernard, Jordana , Wang, Yulun, Broering, Dieter C., Giulianotti, Pier Cristoforo, Fong, Yuman , Raptis, Dimitri , Wren, Sherry M , Aldousari, Saad , Ruurda, Jelle P. H. , Bindal, Vivek , Melstrom, Laleh , Celotto, Francesco , Kudsi, Yusef , Ratti, Francesca , Bernard, Jordana , Kavoussi, Louis R., Fowler, Dennis L. , Anvari, Mehran , Bianco, Francesco Maria , Piccoli, Micaela , Marks, John, Ko, Clifford, Seeliger, Barbara , Hagendoorn, Jeroen , Essani, Rahila, Walsh, R. Matthew , Oleynikov, Dmitry , Hyung, Woo Jin , Hashimoto, Daniel A. , Burt, Bryan M. , Lafaro, Kelly J. , Elli, Fernando, Bianchi, Paolo Pietro, Rashidi, Laila, Hinoul, Piet , Peine, Bill, Woo, Yanghee , Raoof, Mustafa , Jones, Daniel, Deshpande, Supriya , Bröering, Dieter C. , Giulianotti, Pier Cristoforo

Mayo Clinic

World Journal of Surgery | July 14, 2026 | Volume: 50 | Issue: 8 | Pages: 2274-2288

10.1002/wjs.70468 | PMID 42444290 Get It

ABSTRACT Background Implementation of remote robotic‐assisted surgery (rRAS) has the potential to significantly improve access to high‐quality surgical care for patients worldwide. Advances in robotic systems and telecommunications now enable highly reliable, low latency, and cybersecure connectivity. These technological developments, together with the broader adoption of telemedicine, have driven an increasing interest in the implementation of rRAS. Methods The Clinical Robotic Surgery Association (CRSA) convened a conference to develop international clinical recommendations for rRAS using the Danish Model of Consensus. The society identified five key issue categories and invited a panel of experts to address specific questions for each. Panel members and a jury of 10 unbiased, non‐expert in rRAS professionals participated in a day‐long conference on November 19, 2025 (Los Angeles, USA). During the conference, participants presented, discussed, and reached consensus on specific guidelines relevant to each category. Immediately after the conference, the jury reviewed and approved the recommended guidelines. Results Multiple recommendations were approved for each of the following categories: Operating Models, Roles and Responsibilities (2 recommendations), Clinical Pathway (2 recommendations), Emergency Management (8 recommendations), Technical Considerations (5 recommendations), and Medico‐legal and Ethical Considerations (4 recommendations). Conclusions There was consensus that with recent advances in telecommunication and robotic technologies, rRAS can be offered safely and effectively if the identified safeguards are realized. Adoption of rRAS is expected to continue advancing rapidly.
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared With Oral Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized Trial (S21.001)
Macdonald, Loch, Choi, Huimahn, Chou, Sherry, Ducruet, Andrew, Kimberly, W Taylor, Rabinstein, Alejandro, Chou, Sherry, Kimberly, William Taylor , Rabinstein, Alejandro A.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215398 Get It

TRIPLETE But Incomplete? Accounting for Postprogression Therapy When Interpreting Overall Survival
Meimoun, Noah S. , Sherry, Alexander D. , Ludmir, Ethan B. , Lin, Timothy A. , Sherry, Alexander D , Ludmir, Ethan B , Lin, Timothy A

Mayo Clinic

Journal of Clinical Oncology | June 4, 2026 | Volume: 44 | Issue: 23 | Pages: 2254-2255

10.1200/jco-26-00267 | PMID 42241666 Get It

Development and internal validation of a clinical prognostic model for SMARCB1-deficient renal medullary carcinoma (RMC).
Esagian, Stepan M., Yang, Peng, Sheth, Rahul, Karam, Jose A., Tang, Chad, Tannir, N, Msaouel, P, Esagian, Stepan M. , Sherry, Alexander D. , Sheth, Rahul A. , Karam, Jose Antonio , Daw, Najat C. , Tang, Chad , Tannir, Nizar , Msaouel, Pavlos

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16535 Get It

e16535 Background: RMC is a rare and highly aggressive malignancy that predominantly affects young individuals with sickle hemoglobinopathies. Due to its rarity, no validated prognostic models exist to guide clinical decision-making. We aimed to develop and internally validate a prognostic model for patients with RMC using routinely available clinical and laboratory variables. Methods: We analyzed a single-institution cohort of patients with RMC. Candidate variables were identified based on biological plausibility and represented in a directed acyclic graph. Missing data were handled via multiple imputation by chained equations ( m = 50). Variables were ranked using elastic net Cox regression ( α = 0.5, λ = λ min ) with stability selection derived from 100 bootstrap resamples per imputed dataset. Predictors achieving > 60% selection frequency were retained for a nested parsimony analysis. Bootstrap internal validation ( B = 2000) estimated optimism-corrected discrimination and calibration performance, with the calibration slope applied as global shrinkage to penalize final coefficients for overfitting. Clinical utility was evaluated via decision curve analysis (DCA) at 18- and 24-month horizons. Results: Among 180 patients (median age 29; IQR 23–37), 142 deaths occurred with a median follow-up of 12.4 months. The final model included four predictors (Table). The optimism-corrected c-index was 0.667 (optimism = 0.009), and the calibration slope was 0.964, indicating minimal overfitting. Calibration plots showed excellent predicted-observed agreement at 12, 18, 24, and 36 months. DCA showed net benefit across threshold probabilities of 10%–75% at 18 months and 10%–80% at 24 months compared to default strategies. In sensitivity analysis, inclusion of TP53 mutation status improved discrimination ( c -index 0.686) and model fit ( ΔAIC −10.6). An interactive web-based risk calculator was developed to facilitate clinical implementation. Conclusions: This study presents the first internally validated prognostic model for RMC, demonstrating acceptable discrimination and excellent calibration using routinely available variables. By stratifying patients into distinct risk groups, this model may inform treatment intensity—guiding escalation to multi-agent regimens or sequential chemotherapy cycling in high-risk patients, while identifying lower-risk patients who may benefit from de-escalation strategies such as metastasis-directed therapy for oligometastatic disease or consideration of cytoreductive nephrectomy. External validation is warranted. Variable Time Ratio 95% CI p value ECOG performance status 0.64 0.53–0.77 <0.001 Distal (non-retroperitoneal) lymph node metastases 0.69 0.52–0.92 0.011 Neutrophil-to-lymphocyte ratio 0.98 0.94–1.02 0.25 Corrected calcium (mg/dL) 0.77 0.56–1.06 0.10 Sensitivity Analysis Only TP53 Mutation 0.63 0.36-1-10 0.10
Staffing, accepted indications, and dose of Phase II cardiac rehabilitation: country income class and time-based comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s (ICCPR) 2025 Audit Update
Mampuya, Warner , Jiandani, Mariya P , Mbau, Lilian, Rivero, Monserrat Cruz , Anchique, Claudia V. , 丁荣晶 , Schalkwijk, Dinah L. van , Gallagher, Jonathan , Fernández, Rosalia, Maskhulia, L , Martinez, Jimena, Botha, Noel V Hau, Champaiboon, Jirapa , Yokoyama, Miho, Investigators, ICCPR Global Cardiac Rehabilitation Audit Update, Akinci, Buket, Carson, Rachael Pamela, Quesada-Chaves, Daniel F, Norekvål, Tone M, Kouidi, Evangelia , Таргыновна, Аймакова Гульсим, Quito, Benjamin Jose, Lima de Melo Ghisi, Gabriela , Turk-Adawi, Karam , Mampuya, Warner M , Jiandani, Mariya P , Mbau, Lilian , Cruz Rivero, Monserrat , Anchique, Claudia V , Gallagher, Jonathan , Gaye, Ngone Diaba , Kim, Won-Seok , Seron, Pamela , Maskhulia, Lela , Batalik, Ladislav , Chen, Ssu-Yuan , Supervía, Marta , Champaiboon, Jirapa , Grace, Sherry L , Mettananda, Chamila Dinushi Kukulege , Baťalík, Ladislav , Yokoyama, Miho Nishitani , Grace, Sherry L. , Akıncı, Buket , Candelaria, Dion , Quesada-Chaves, Daniel, Norekvål, Tone M. , Szadkowska, Iwona , Jug, Borut , Aimakova, Gulsim T., Radi, Basuni

Mayo Clinic

European Journal of Preventive Cardiology | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag292 | PMID 42207983 Get It

Abstract Aims To characterize global variation in cardiac rehabilitation (CR) staffing, indications, and prescribed dose by country income classification and compare findings with the International Council of Cardiovascular Prevention and Rehabilitation’s 2016 Global Audit. Methods and results Cross-sectional REDCap survey of Phase II/post-discharge CR programmes (May–September 2025). Outcomes were multidisciplinary team size/composition, accepted cardiac and non-cardiac indications, and centre-based CR dose. Comparisons were made across World Bank country income classifications and Audit decade (2016 vs. 2025). Of 7025 programmes identified globally, 1505 (median programme response rate = 62%/country) initiated a survey, from 90/113 (80%) countries with CR. CR was delivered by a multidisciplinary team of 7 (median; P25–P75 = 5–8; nurses, physiotherapists, cardiologists, and dietitians most common); teams were smaller in low-income countries (median = 4; P &lt; 0.001), and physician specialty varied. Non-low-income programmes consistently accepted (≥90%) patients with acute coronary syndrome, with programmes in low-income countries less often accepting related interventions (e.g. surgery: low-income 0% vs. high-income 97%; P &lt; 0.01), but non-cardiac indications were more frequently accepted (e.g. primary prevention, diabetes, and lung disease). Acceptance of heart failure increased compared with the previous Audit (70% vs. 87%; P &lt; 0.001). Centre-based programmes prescribed a median of 20 h (P25–P75 = 12–30), typically two sessions/week over 8 weeks. Globally, 65 (72%) countries prescribed a median ≥12 sessions/programme. Programmes in upper-middle-income countries prescribed more sessions (median = 24, P25–P75 = 12–36; P &lt; 0.001). Dose did not differ meaningfully between Audits (P = 0.07). Conclusion CR programmes globally are offered by small, but multidisciplinary teams. They accept guideline-indicated patients, with applicable variation by context. Insufficient dose in one-quarter of countries underscores investment need.
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
Sherry, Alexander D. , Haymaker, C, Wang, S, Liu, S, Medina-Rosales, Marina Nayeli , Seo, Aaron, Reddy, Jay P. , Mayo, Lauren L., Pant, Shubham , Kovitz, Craig A., Ha, Chul S., Smith, BD, Gomez, Daniel, Cohen, Lorenzo , Tannir, Nizar, Corn, Paul G., Siddiqui, Bilal A. , Ludmir, Ethan B., Tang, Chad , Haymaker, Cara , Liu, Suyu , Haymaker, Cara , Wang, Shuqi , Liu, Suyu , Bathala, Tharakeswara K , Medina-Rosales, Marina N , Reddy, Jay P , Chun, Stephen G , Walker, Gary , Pant, Shubham , Zhao, Dan , Kovitz, Craig A , Smith, Benjamin D , Gomez, Daniel , Cohen, Lorenzo , Koong, Albert C , Reuben, Alexandre , Tannir, Nizar , Tran, Phuoc T , Siddiqui, Bilal A , Subudhi, Sumit Kumar , Msaouel, Pavlos , Ludmir, Ethan B , Tang, Chad , Sherry, Alexander D , Seo, Aaron , Hara, Kieko , Chun, Stephen G. , Mayo, Lauren L. , Zhao, Dan , Ramirez, David Luis , Ha, Chul S. , Corn, Paul Gettys , Msaouel, Pavlos , Ludmir, Ethan B.

Mayo Clinic

Journal of Clinical Oncology | May 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-02856 | PMID 42142259 Get It

PURPOSE We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology Trials
Sherry, Alexander D. , Msaouel, Pavlos, Kupferman, Gabrielle S. , Lin, Timothy A. , Jaoude, J. Abi, Kouzy, Ramez, El-Alam, Molly B , Patel, Roshal , Koong, Alex , Lin, Christine , Beck, Esther J., Fuller, Clifton David, Ludmir, Ethan B, Msaouel, Pavlos , Kouzy, Ramez , Jaoude, Joseph Abi , Msaouel, Pavlos , Abi Jaoude, Joseph , Kouzy, Ramez , Passy, Adina H , Miller, Avital M , Beck, Esther J , Fuller, Clifton David , Meirson, Tomer , McCaw, Zachary , Ludmir, Ethan B , Sherry, Alexander D , Lin, Timothy A , Miller, Avital M. , Meirson, Tomer , McCaw, Zachary R. , Ludmir, Ethan B.

Mayo Clinic

JCO Clinical Cancer Informatics | May 1, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1200/cci-25-00303 | PMID 42066235 Get It

PURPOSE Most oncology trials define superiority according to dichotomized P value thresholds, which are frequently misinterpreted. Posterior probability, however, directly estimates the probability of the hypothesis at hand. Here, we reanalyze a large collection of modern phase III trials and benchmark posterior probability versus the standard trial interpretation based on statistical significance. METHODS Outcomes from 194,129 patients were manually reconstructed from the primary end points of 230 phase III, superiority-design oncology trials. Posterior probabilities of treatment effect were then calculated across multiple priors and several effect sizes of clinical relevance, including minimum clinically important difference (MCID) defined as hazard ratio (HR) < 0.8 per ASCO criteria or HR < 0.64 per European Society of Medical Oncology (ESMO) criteria. RESULTS All trials interpreted as superior using P value thresholds had probabilities >90% for achieving at least marginal benefits (HR < 1). However, only 62% of positive trials (74/120) had >90% probabilities of achieving the ASCO MCID (HR < 0.8), even under an enthusiastic prior, including 70% of trials (57/82) leading to regulatory approval. Only 30% of positive trials (36/120) had >90% probability of achieving the ESMO MCID (HR < 0.64). Conversely, 24% of trials (26/110) interpreted as not superior had >90% probability of achieving marginal benefits (HR < 1), even under a skeptical prior. CONCLUSION Bayesian models, although often in agreement with statistical significance thresholds, add considerable unique interpretative value for a subset of phase III oncology trials. Posterior probability may provide a solution for overcoming the discrepancies between refuting the null hypothesis and detecting clinically relevant effects.
Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Hashmi, Ayesha , Linford, Jessica , Chauhan, Pradeep S, Parikh, K, Pillai, Malvika , Guittar, John , Ben-Shachar, Rotem , Patel, Jyoti , Nimeiri, Halla , Bergsagel, Matteo , Park, S, Olivier, Kenneth R. , Owen, Dawn , Lee, K.N. , Morgensztern, Daniel, Robinson, Clifford G, Bergom, Carmen , Samson, Pamela , Pellini, B., Vlacich, Gregory , Chaudhuri, Aadel A, Chauhan, Pradeep S. , Ben‐Shachar, Rotem , Chauhan, Pradeep S , Parikh, Kaushal , Patel, Jyoti , Semenkovich, Nicholas P , Park, Sean S , Owen, Dawn , Routman, David M , Lee, Katie N , Sherry, Alexander D , Mansfield, Aaron S , Morgensztern, Daniel , Govindan, Ramaswamy , Robinson, Clifford , Bergom, Carmen , Waqar, Saiama N , Samson, Pamela P , Pellini, Bruna , Vlacich, Gregory R , Chaudhuri, Aadel A , Patel, Jyoti D. , Semenkovich, Nicholas P. , Routman, David M. , Sherry, Alexander D. , Mansfield, Aaron S. , Morgensztern, Daniel , Govindan, Ramaswamy , Pellini, Bruna , Chaudhuri, Aadel A.

Mayo Clinic

Clinical Cancer Research | April 30, 2026 | Volume: 32 | Issue: 14 | Pages: 2945-2956

10.1158/1078-0432.ccr-25-4983 | PMID 42059900 Get It

Abstract Purpose: Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT). Experimental Design: In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309). Results: Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P &lt; 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P &lt; 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P &lt; 0.001). ctFE remained associated with survival in both validation cohorts. Conclusions: Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.